The Unmet Need in Anaphylaxis

Anaphylaxis is a severe, life‑threatening allergic reaction.

Immediate delivery of epinephrine (adrenaline) is the only first-line, life-saving treatment for anaphylaxis.

However, delays in treatment remain common, leaving many patients at risk.

Emergency team moving a patient on a trolley down a hospital corridor
Doctor with a clipboard talking with a smiling mother and her young son in a clinic

Clinical-stage Development

De Motu Cordis is a clinical-stage drug-device company developing an investigational epinephrine inhaler for the emergency treatment of anaphylaxis.

Expert Leadership

De Motu Cordis is led by an experienced team with expertise in critical care medicine, medical device development, clinical research, commercialisation, and business growth.

De Motu Cordis expertise: critical care medicine, device development, clinical research, commercial strategy and business growth

Our Story

De Motu Cordis is a clinical-stage drug-device company founded in Brisbane, Australia by globally recognised intensive care specialist, researcher, entrepreneur and founder Professor John Fraser AO. The company was established to advance innovative technologies designed to address important challenges in emergency medical care.

Investors & Partners

De Motu Cordis has been supported to date by a group of high-net-worth individuals and family offices. The company is preparing for a Series A capital raise and welcomes engagement with prospective investors and strategic partners.

Two colleagues reviewing a chart on a laptop in an office overlooking the city

Latest News and Media

  • Meet our new Chief Operating Officer, Ludo Bonnet

    In an industry often defined by compliance and incremental progress, Ludovic “Ludo” Bonnet has built a career on moving with both precision and pace.

  • Unlock the MRFF – Professor John Fraser AO Joins Call for Action on Medical Research Funding

    De Motu Cordis Founder and Chief Medical Officer, Professor John Fraser AO, is among more than 60 of Australia’s most eminent scientists and industry leaders calling on the federal government to unlock the Medical Research Future Fund (MRFF).

  • Sonia Barber, DMC Legal Counsel: Redefining what is possible in emergency drug delivery
    Redefining What’s Possible in Emergency Drug Delivery

    At the demanding intersection where innovation meets commercial reality, DMC’s Legal Counsel, Sonia Barber stands out as a leader who speaks fluently across law, business, science and global strategy.